Lantern Pharma Obtains Approval for LP-300 Phase 2 Part 2 Clinical Trial in Taiwan
LTRN Lantern Pharma Inc
$0.84 -7.93%
View chart & analysis → - 1Lantern Pharma has secured regulatory and Institutional Review Board (IRB) approval to initiate Part 2 of the Phase II HARMONIC clinical trial for LP-300 in Taiwan.
- 2Eligible participants can receive up to 8 cycles of LP-300 under the revised protocol, and major sites in Taiwan received IRB approval and began patient screening on September 29, 2026.
- 3Following the completion of registration at five centers in Japan in 2025, the clinical stage is now proceeding in Taiwan.
So what's the key point?
Lantern Pharma has entered a stage of testing a new drug in Taiwan. Following Japan, the company is continuing its clinical research stages in Taiwan as well.
Source Clinical Trials Arena · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.